click enter text
initi under-perform
summari invest thesi direct cautiou
sinc initi current under-perform rate
technic rate downgrad stori line remain
competit growth next year
substanti pressur earn begin pharma sector investor
often begin discount lay ahead year advanc singl
product concentr risk humira degre vastli exce
compani cover product unfortun tail end life
cycl investor know profit drug may still
underestim profit realli in- outsid us
eu biosimilar humira begin launch month us
belief new money sit one given uncertainti
model rate eros pipelin lack
dynam think under-perform peer support view
partli come stock drug group defens
summer ralli share stay flat engag larger
distinct possibl otherwis get hand meaning new
product perhap stori get interest
exhibit show incom statement product revenu balanc
sheet cash flow forecast
initi report price octob
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
page
incom statement oper expens foreign exchang incom expens outstand margin total profit profit profit incom growth oper revenu earli phase total
exhibit wr balanc sheet cash flow statement
page
flow statement incom intang chang oper asset flow oper activ busi net cash acquisit properti flow invest activ chang short-term issuanc lt lt debt leas treasuri flow financ activ fx cash increas decreas cash sheet cash properti plant goodwil current term non-curr stock held paid-in comprhens sharehold liabil sharehold
